Norgine Receives Approval from Swissmedic for PEDMARQSI® to Combat Hearing Loss in Children Norgine's PEDMARQSI® has gained regulatory approval in Switzerland, marking a significant step in preventing cisplatin-induced hearing loss in pediatric patients. This innovative treatment addresses a critical medical need.

Norgine Receives Approval from Swissmedic for PEDMARQSI® to Combat Hearing Loss in Children #None #Norgine #CISPLATIN #PEDMARQSI

Norgine's PEDMARQSI Gets Swissmedic Green Light: A Breakthrough in Preventing Hearing Loss in Children Norgine has received Swissmedic approval for PEDMARQSI, a groundbreaking treatment to prevent cisplatin-induced hearing loss in young cancer patients.

Norgine's PEDMARQSI Gets Swissmedic Green Light: A Breakthrough in Preventing Hearing Loss in Children #Amsterdam #Switzerland #Norgine #PEDMARQSI #Swissmedic

Norgine's PEDMARQSI® Approved to Prevent Cisplatin-Induced Hearing Loss in Children Norgine has announced that Swissmedic has approved PEDMARQSI®, the first treatment for preventing cisplatin-induced hearing loss in children, fulfilling an unmet medical need.

Norgine's PEDMARQSI® Approved to Prevent Cisplatin-Induced Hearing Loss in Children #Amsterdam #Switzerland #Norgine #CISPLATIN #PEDMARQSI